Sorry, I apparently did not make my point clear. I
Post# of 153887
(Total Views: 721)
Posted On: 09/13/2020 11:23:47 AM
Re: Goosebumps #55569
Sorry, I apparently did not make my point clear. I preface this by saying again I am long CYDY. In fact I own outright nearly as many shares of CYDY as I control of IMMU. I do believe in CYDY’s potential to impact the treatment of a wide range of maladies because of its mode of operation. It seems obvious that IMMU product can not do the same since it is working in a very different way, However, and this is my point, to dismiss Trodelvy out of hand as merely a second or third line treatment against mTNBC does not acknowledge the research that is being reported on this week in Europe nor does it take into account the progress in research for other indications. You did not need to reproduce the label for Trodelvy. I like numerous cancer researchers and doctors all over the US have read the label. Those researchers and doctors have chosen to use the drug because the counter indications are not of the type and level of severity that can not be dealt with in most patients. Your arguments sound like the shorts that inhabit the IMMU boards but hopefully you are not from the dark side of the shorters of potentially life saving medications. I will personally never live in that dark world.
CYDY has a great product. Unfortunately, unlike IMMU, so far they have not been able to get it to market for any of it many potential applications. That, in my opinion, is mind boggling and tragic. Hopefully, this coming week we will hear a report that will give hope that the long road to a market for at least one malady will come to an end. In this way it is obvious that CYDY is behind IMMU in the ultimate goal of helping severely ill people. I suspect that CYDY will eventually catch up if our understanding of what Leronlimab does is correct and is borne out in real life marketing of it with those who need it the most. At the same time, when it comes to cancer, every treatment that can extend the lives of its victims should be welcomed until a better treatment is found. The reality is that many treatments are needed over a period of time for those inflicted with the most aggressive forms. I don't want to put down any available treatment until the ultimate treatment is found that by itself can cure the big “C”. Perhaps CYDY is leading the way to the ultimate treatment but much work needs to be done to prove that.
CYDY has a great product. Unfortunately, unlike IMMU, so far they have not been able to get it to market for any of it many potential applications. That, in my opinion, is mind boggling and tragic. Hopefully, this coming week we will hear a report that will give hope that the long road to a market for at least one malady will come to an end. In this way it is obvious that CYDY is behind IMMU in the ultimate goal of helping severely ill people. I suspect that CYDY will eventually catch up if our understanding of what Leronlimab does is correct and is borne out in real life marketing of it with those who need it the most. At the same time, when it comes to cancer, every treatment that can extend the lives of its victims should be welcomed until a better treatment is found. The reality is that many treatments are needed over a period of time for those inflicted with the most aggressive forms. I don't want to put down any available treatment until the ultimate treatment is found that by itself can cure the big “C”. Perhaps CYDY is leading the way to the ultimate treatment but much work needs to be done to prove that.
(11)
(0)